Alogliptin / Pioglitazone
Alogliptin/pioglitazone is a two-medicine combination tablet used alongside diet and exercise to improve blood sugar control in adults with type 2 diabetes.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 2 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
This medicine can cause or worsen heart failure in some people. Pioglitazone — one of the two active ingredients — can cause the body to hold onto extra fluid. That fluid buildup can put more strain on the heart and lead to congestive heart failure (when the heart can't pump well enough). Watch for signs like rapid or unexpected weight gain, swelling in the legs or ankles, or shortness of breath — and report them to your doctor immediately. This medicine should not be started in anyone who already has moderate or severe heart failure (NYHA Class III or IV), and it is not recommended for people with any symptomatic heart failure. If heart failure develops while you are taking this medicine, your doctor may lower your dose or stop it altogether.
📖 Alogliptin / Pioglitazone: Patient Information Guide
A plain-language walkthrough of Alogliptin / Pioglitazone — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Alogliptin/pioglitazone is a combination medicine approved to help improve blood sugar control in adults with type 2 diabetes, used alongside diet and exercise.
- Alogliptin and Pioglitazone tablets are indicated as an adjunct to diet and exercise to improve blood sugar (glycemic) control in adults with type 2 diabetes
- Oseni is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes
- Neither product is recommended for people with type 1 diabetes
- Neither product is recommended for use in children — safety and effectiveness have not been established in pediatric patients
⚙️How it works▾
This tablet contains two medicines that lower blood sugar in different ways. Alogliptin blocks an enzyme called DPP-4, which normally destroys natural hormones (incretins like GLP-1 and GIP) released after eating. By blocking DPP-4, alogliptin lets those hormones stay active longer — prompting the pancreas to release more insulin when blood sugar is high, and telling the liver to produce less sugar. Pioglitazone belongs to a class called thiazolidinediones. It activates receptors (PPARγ) inside cells in fat, muscle, and the liver, making those cells more sensitive and responsive to insulin. This reduces insulin resistance — meaning the body's own insulin can work more effectively to move sugar out of the bloodstream.
Together, alogliptin and pioglitazone complement each other: one boosts the natural signals to release insulin, while the other helps the body actually respond to that insulin.
💊How it's taken▾
Alogliptin/pioglitazone tablets (including Oseni) are taken orally once a day and can be taken with or without food — food does not meaningfully change how much of the medicine is absorbed. Your prescriber will individualize the strength based on your current diabetes treatment and medical history, staying within the approved maximum daily dose. Liver tests are recommended before starting, and kidney function should be checked as well, since the alogliptin portion may require dose adjustment in people with reduced kidney function.
- Take it at roughly the same time each day
- Follow your prescriber's and pharmacist's instructions for your specific dose
- Do not adjust or exceed your prescribed dose without talking to your doctor first
🤒Side effects — in detail▾
The most commonly reported side effects (occurring in at least 4% of patients in clinical trials) include:
- Nasopharyngitis (stuffy or runny nose, sore throat)
- Upper respiratory tract infections (cold-like symptoms)
- Back pain
- Headache
- Sinusitis
- Muscle aches (myalgia)
- Swelling in the hands, ankles, or feet (edema from fluid retention)
- Low blood sugar (hypoglycemia), especially if also taking insulin or a sulfonylurea
More serious reactions — including heart failure, pancreatitis, liver injury, severe allergic reactions, bladder cancer, bone fractures, macular edema, severe joint pain, and a blistering skin reaction called bullous pemphigoid — are less common but require prompt medical attention if they occur.
⚠️Warnings & precautions▾
- Heart failure: Pioglitazone can cause fluid retention that may trigger or worsen congestive heart failure, especially when combined with insulin. Watch for rapid weight gain, leg swelling, or shortness of breath. Do not start this medicine if you have NYHA Class III or IV heart failure.
- Pancreatitis: Acute pancreatitis (inflamed pancreas) has been reported. Severe stomach pain radiating to the back is a warning sign — stop the medicine and seek care immediately.
- Liver injury: Postmarketing reports of serious liver failure have occurred. Liver tests are done before starting. Report yellowing of skin or eyes, dark urine, or unusual fatigue right away.
- Bladder cancer: Pioglitazone may be associated with an increased risk of bladder cancer. It should not be used in patients with active bladder cancer and should be used cautiously in those with a prior history.
- Bone fractures: An increased rate of fractures has been observed in women taking pioglitazone. Bone health should be monitored.
- Serious allergic reactions: Anaphylaxis, angioedema, and severe skin reactions (including Stevens-Johnson syndrome) have been reported with alogliptin. Seek emergency help immediately if these occur.
- Macular edema: Fluid buildup behind the eye causing vision changes has been reported. Report any sudden visual changes to your doctor.
- Severe joint pain: Disabling arthralgia has been reported with DPP-4 inhibitors. If you develop severe joint pain, talk to your doctor about whether this medicine may be the cause.
🔀What it interacts with▾
Several medicines can affect how well pioglitazone or alogliptin works, or raise the risk of side effects:
- Gemfibrozil and other strong CYP2C8 inhibitors: These significantly raise pioglitazone levels in the blood, increasing side-effect risk. The daily dose of pioglitazone in this combination must be limited when taken with these medicines.
- Rifampin and other CYP2C8 inducers: These can lower pioglitazone levels, potentially reducing blood sugar control. Blood sugar monitoring is important if these are started or stopped.
- Topiramate (a seizure/migraine medicine): May reduce pioglitazone exposure; blood sugar should be monitored more closely.
- Insulin and insulin secretagogues (e.g., sulfonylureas like glipizide or glyburide): Combining with this tablet raises the risk of low blood sugar. Lower doses of insulin or the secretagogue may be needed.
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Do not take this medicine if you have NYHA Class III or IV heart failure (moderate to severe) — it is contraindicated
- Do not take it if you have had a serious allergic reaction (anaphylaxis, angioedema, severe skin reactions) to alogliptin or pioglitazone previously
- Tell your doctor about any history of heart failure, fluid retention, or kidney disease — closer monitoring or a lower starting dose may be needed
- Tell your doctor about any liver disease or abnormal liver tests — liver function should be checked before starting
- Tell your doctor if you have or have had bladder cancer — this medicine should not be used with active bladder cancer
- Premenopausal women: Pioglitazone may cause ovulation in women who are not regularly ovulating, raising the chance of unintended pregnancy — discuss contraception with your doctor
- Pregnant women: Limited safety data exists; poorly controlled diabetes in pregnancy carries its own serious risks — talk with your prescriber about the best treatment plan
- Breastfeeding: It is not known whether this medicine passes into human breast milk — discuss risks and benefits with your doctor
- Children: Safety and effectiveness have not been established; not recommended for pediatric patients
- Older adults (65+): No major differences in safety or effectiveness have been identified, but kidney function should be assessed since alogliptin may need dose adjustment with declining kidney function
🚑If you take too much▾
If you or someone else takes too much of this medicine, call the Poison Help Line at 1-800-222-1222 or seek emergency medical care. Supportive medical monitoring and treatment will be provided based on symptoms. Alogliptin is only minimally removed by dialysis (about 7% over a three-hour session), so dialysis is unlikely to help in an overdose situation.
📡Pharmacodynamics — effects in the body▾
In clinical studies, alogliptin reduced blood sugar levels after meals and lowered glucagon while raising active GLP-1 levels. Pioglitazone improved the body's sensitivity to insulin, lowering blood sugar and insulin levels over time, and also led to measurable improvements in blood fats — including decreases in triglycerides and increases in HDL ("good") cholesterol. When the two medicines were used together, the combination produced greater reductions in triglycerides and greater increases in HDL cholesterol than either medicine alone. LDL and total cholesterol did not show consistent changes. Alogliptin did not cause any meaningful changes in heart rhythm (QT interval) even at doses far exceeding the normal clinical dose.
🔬Pharmacokinetics — how your body processes it▾
Both alogliptin and pioglitazone are well absorbed after oral dosing. Alogliptin has nearly complete (approximately 100%) absorption and can be taken with or without food with no meaningful difference in exposure. Pioglitazone reaches peak blood levels within about two hours; food slightly delays but does not reduce its absorption. Alogliptin undergoes very little breakdown in the body — most of it is excreted unchanged in the urine — while pioglitazone is extensively metabolized in the liver (mainly by the CYP2C8 enzyme), with active metabolites that contribute significantly to its overall effect. Pioglitazone and its active metabolites reach steady levels in the blood within about seven days of daily dosing. Alogliptin is only 20% bound to blood proteins, while pioglitazone and its active metabolites are very extensively protein-bound (over 98–99%).
📦How to store it▾
Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) . protect from moisture and humidity.
📄 Written from Alogliptin / Pioglitazone’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Alogliptin / Pioglitazone — the kind of thing our pharmacy team would talk through with you at the counter.
What exactly does this medicine do for my diabetes? ▾
Can I take this pill with food, or does it have to be on an empty stomach? ▾
I heard this medicine can affect the heart. Should I be worried? ▾
What side effects are most likely, and which ones should make me call my doctor? ▾
Are there medicines or supplements I should avoid while taking this? ▾
I'm a woman who hasn't gone through menopause yet. Is there anything I should know? ▾
Is Alogliptin / Pioglitazone available over the counter? ▾
When was Alogliptin / Pioglitazone first available? ▾
Who makes Alogliptin / Pioglitazone? ▾
💬 Answers drafted from Alogliptin / Pioglitazone’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Alogliptin / Pioglitazone comes
Alogliptin / Pioglitazone is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Tablet
How this form is used
- Alogliptin and Pioglitazone tablets are used as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes
- Oseni is used as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes
- Neither Alogliptin and Pioglitazone tablets nor Oseni are recommended for type 1 diabetes
- Alogliptin and Pioglitazone tablets and Oseni may be taken with or without food
- Both Alogliptin and Pioglitazone tablets and Oseni are taken orally once daily
- Liver tests should be obtained before starting Alogliptin and Pioglitazone tablets or Oseni
- Kidney function should be assessed before starting Alogliptin and Pioglitazone tablets or Oseni, as dose adjustment may be needed in people with reduced kidney function
📊 Alogliptin / Pioglitazone across the U.S. market
How Alogliptin / Pioglitazone appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Alogliptin / Pioglitazone is used
A general measure of how commonly Alogliptin / Pioglitazone is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Alogliptin / Pioglitazone is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Alogliptin / Pioglitazone prescribed? Of the 1,596 medications we measure, Alogliptin / Pioglitazone ranks #1,314 by Medicaid prescriptions — more than 18% of them.
Utilization by Alogliptin / Pioglitazone product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
alogliptin 25 MG / pioglitazone 30 MG Oral Tablet Most dispensed
Summed across the 1 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1368431
alogliptin 25 MG / pioglitazone 15 MG Oral Tablet
Summed across the 1 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1368424
alogliptin 25 MG / pioglitazone 45 MG Oral Tablet
Summed across the 1 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1368438
alogliptin 12.5 MG / pioglitazone 30 MG Oral Tablet
Summed across the 1 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1368410
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Alogliptin / Pioglitazone, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 4 of 24 listed Alogliptin / Pioglitazone NDCs with Medicaid activity.
🔍 Compare Alogliptin / Pioglitazone products
A representative set of FDA-listed product records for Alogliptin / Pioglitazone — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Tablet | ||||
| ALOGLIPTIN BENZOATE 12.5 mg/1; PIOGLITAZONE HYDROCHLORIDE 30 mg | Oral | Padagis Israel Pharmaceuticals Ltd | NDA AUTHORIZED GENERIC | View NDC → |
| ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 15 mg | Oral | Padagis Israel Pharmaceuticals Ltd | NDA AUTHORIZED GENERIC | View NDC → |
| ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 30 mg | Oral | Padagis Israel Pharmaceuticals Ltd | NDA AUTHORIZED GENERIC | View NDC → |
| ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 45 mg | Oral | Padagis Israel Pharmaceuticals Ltd | NDA AUTHORIZED GENERIC | View NDC → |
| 12.5; 15 mg/1; mg | Oral | Padagis Israel Pharmaceuticals Ltd | NDA AUTHORIZED GENERIC | View NDC → |
| 12.5; 30 mg/1; mg | Oral | Padagis Israel Pharmaceuticals Ltd | NDA AUTHORIZED GENERIC | View NDC → |
| 12.5; 45 mg/1; mg | Oral | Padagis Israel Pharmaceuticals Ltd | NDA AUTHORIZED GENERIC | View NDC → |
| 25; 15 mg/1; mg | Oral | Padagis Israel Pharmaceuticals Ltd | NDA AUTHORIZED GENERIC | View NDC → |
| 25; 30 mg/1; mg | Oral | Padagis Israel Pharmaceuticals Ltd | NDA AUTHORIZED GENERIC | View NDC → |
| 25; 45 mg/1; mg | Oral | Padagis Israel Pharmaceuticals Ltd | NDA AUTHORIZED GENERIC | View NDC → |
| ALOGLIPTIN BENZOATE 12.5 mg/1; PIOGLITAZONE HYDROCHLORIDE 30 mg | — | Takeda GmbH | DRUG FOR FURTHER PROCESSING | View NDC → |
| ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 15 mg | — | Takeda GmbH | DRUG FOR FURTHER PROCESSING | View NDC → |
| ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 30 mg | — | Takeda GmbH | DRUG FOR FURTHER PROCESSING | View NDC → |
| ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 45 mg | — | Takeda GmbH | DRUG FOR FURTHER PROCESSING | View NDC → |
| ALOGLIPTIN BENZOATE 12.5 mg/1; PIOGLITAZONE HYDROCHLORIDE 15 mg | — | Takeda Pharmaceutical Co LTD | DRUG FOR FURTHER PROCESSING | View NDC → |
| ALOGLIPTIN BENZOATE 12.5 mg/1; PIOGLITAZONE HYDROCHLORIDE 30 mg | — | Takeda Pharmaceutical Co LTD | DRUG FOR FURTHER PROCESSING | View NDC → |
| ALOGLIPTIN BENZOATE 12.5 mg/1; PIOGLITAZONE HYDROCHLORIDE 45 mg | — | Takeda Pharmaceutical Co LTD | DRUG FOR FURTHER PROCESSING | View NDC → |
| ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 15 mg | — | Takeda Pharmaceutical Co LTD | DRUG FOR FURTHER PROCESSING | View NDC → |
| ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 30 mg | — | Takeda Pharmaceutical Co LTD | DRUG FOR FURTHER PROCESSING | View NDC → |
| ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 45 mg | — | Takeda Pharmaceutical Co LTD | DRUG FOR FURTHER PROCESSING | View NDC → |
| ALOGLIPTIN BENZOATE 12.5 mg/1; PIOGLITAZONE HYDROCHLORIDE 30 mg | Oral | Takeda Pharmaceuticals America, Inc. | NDA | View NDC → |
| ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 15 mg | Oral | Takeda Pharmaceuticals America, Inc. | NDA | View NDC → |
| ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 30 mg | Oral | Takeda Pharmaceuticals America, Inc. | NDA | View NDC → |
| ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 45 mg | Oral | Takeda Pharmaceuticals America, Inc. | NDA | View NDC → |
| 12.5; 15 mg/1; mg | Oral | Takeda Pharmaceuticals America, Inc. | NDA | View NDC → |
| 12.5; 30 mg/1; mg | Oral | Takeda Pharmaceuticals America, Inc. × 2 listings | NDA | View NDC → |
| 12.5; 45 mg/1; mg | Oral | Takeda Pharmaceuticals America, Inc. | NDA | View NDC → |
| 25; 15 mg/1; mg | Oral | Takeda Pharmaceuticals America, Inc. × 2 listings | NDA | View NDC → |
| 25; 30 mg/1; mg | Oral | Takeda Pharmaceuticals America, Inc. × 2 listings | NDA | View NDC → |
| 25; 45 mg/1; mg | Oral | Takeda Pharmaceuticals America, Inc. × 2 listings | NDA | View NDC → |
Showing 34 of 34 products — FDA National Drug Code Directory. See every product, package size and price: browse all 34 Alogliptin / Pioglitazone NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Alogliptin / Pioglitazone — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Alogliptin / Pioglitazone in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Alogliptin / Pioglitazone went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one exact multiple-ingredient concept (MIN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). A product with a different ingredient combination belongs on a different page.
RxCUI 1368402 1 dose form · 6 strengths
-
Dose form (SCDF) Oral Tablet RxCUI 1368401In current FDA listingsClinical drug / strength (SCD) alogliptin 12.5 MG / pioglitazone 15 MGRxCUI 1368403alogliptin 12.5 MG / pioglitazone 30 MGRxCUI 1368410alogliptin 12.5 MG / pioglitazone 45 MGRxCUI 1368417alogliptin 25 MG / pioglitazone 15 MGRxCUI 1368424alogliptin 25 MG / pioglitazone 30 MGRxCUI 1368431alogliptin 25 MG / pioglitazone 45 MGRxCUI 1368438
Look up RxCUI 1368402 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Alogliptin / Pioglitazone is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
RxNorm drug class
Alogliptin / Pioglitazone belongs to the Dipeptidyl Peptidase 4 Inhibitor class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 2 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Padagis Israel Pharmaceuticals Ltd is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.